lcerative Colitis Market Growth Outlook Through 2024-2033

Overview and Scope
Ulcerative colitis is a chronic inflammatory bowel disease (IBD) and is categorized as an autoimmune disorder in which the immune system attacks healthy tissue of the large intestine and causes inflammation on the superficial layer of the large intestine. It includes symptoms of diarrhea, weight loss, abdominal cramping, anemia, blood or pus in bowel movements, and others.

Sizing and Forecast
The ulcerative colitis market size has grown strongly in recent years. It will grow from $6.84 billion in 2023 to $7.35 billion in 2024 at a compound annual growth rate (CAGR) of 7.4%. The growth in the historic period can be attributed to prevalence of ulcerative colitis, innovations in drug development, biologics and targeted therapies, improved treatment guidelines, patient advocacy and support groups.

The ulcerative colitis market size is expected to see strong growth in the next few years. It will grow to $9.48 billion in 2028 at a compound annual growth rate (CAGR) of 6.6%. The growth in the forecast period can be attributed to advancements in telemedicine, focus on early intervention, biosimilars market growth, research in gut microbiome, emergence of novel therapies. Major trends in the forecast period include patient-centric approaches, global collaborations in research, integration of digital health solutions, innovations in drug delivery, topical and localized therapies.

To access more details regarding this report, visit the link:
https://www.thebusinessresearchcompany.com/report/ulcerative-colitis-global-market-report

Segmentation & Regional Insights
The ulcerative colitis market covered in this report is segmented –

1) By Drug Type: Anti-Inflammatory Drugs, Anti-TNF Biologics, Immunosuppressant, Calcineurin Inhibitors, Other Drug Types
2) By Disease Type: Ulcerative Proctitis, Proctosigmoiditis, Left-sided Colitis, Pancolitis or Universal Colitis, Fulminant Colitis
3) By Molecule Type: Biologics, Small Molecules
4) By Route of Administration: Oral, Injectables
5) By End-User: Hospital Pharmacies, Retail Pharmacies, Drug Store, Other End-User

North America was the largest region in the ulcerative colitis market in 2023. The regions covered in the ulcerative colitis market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Intrigued to explore the contents? Secure your hands-on sample copy of the report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=10328&type=smp

Major Driver Impacting Market Growth 
The increasing healthcare expenditure is expected to propel the growth of the ulcerative colitis market going forward. Health expenditure refers to all spending for health-related services, family planning activities, nutrition activities, and emergency help, but excludes expenses for drinking water and sanitation. Increased healthcare spending can benefit ulcerative colitis sufferers by improving access to medical care and therapies. Hospitalization for ulcerative colitis can be significant, and hospital readmissions for flares can result in higher mortality and healthcare costs. For instance, in March 2022, according to the 2021–2030 National Health Expenditure (NHE) report published by the Centers for Medicare & Medicaid Services, a US-based Department of Health and Human Services department, the annual increase in national health spending was predicted to average 5.1% between 2021 and 2030, reaching approximately $6.8 trillion by 2030. Additionally, throughout the period 2021–2030, Medicare expenditures are expected to expand at a 7.2% annual rate, while Medicaid spending is expected to grow at a 5.6% annual rate. Therefore, increasing healthcare expenditures are driving the growth of the ulcerative colitis market.

Key Industry Players
Major companies operating in the ulcerative colitis market report are Abbott Laboratories, AbbVie Inc., Ajinomoto Co. Inc., AstraZeneca plc, Bausch Health Companies Inc., Eli Lilly and Co., Johnson & Johnson, Index Pharmaceuticals Holdings AB, GlaxoSmithKline plc, Merck & Co. Inc., Novartis AG, Pfizer Inc., Sanofi S.A., Allergan plc, Bayer AG, BioLineRx Ltd., Celgene Corporation, Bristol Myers Squib Company, Takeda Pharmaceutical Company Limited, Genentech Inc., UCB S.A., Protagonist Therapeutics, Shire plc, Warner Chilcott, Prometheus Laboratories Inc., Cosmo Pharmaceuticals, Dr. Falk Pharma GmbH, Tillotts Pharma AG, Ferring Pharmaceuticals Inc., Salix Pharmaceuticals Inc.

The ulcerative colitis market report table of contents includes:

1. Executive Summary
2. Ulcerative Colitis Market Characteristics
3. Ulcerative Colitis Market Trends And Strategies
4. Ulcerative Colitis Market – Macro Economic Scenario
5. Global Ulcerative Colitis Market Size and Growth
.
.
.
31. Global Ulcerative Colitis Market Competitive Benchmarking
32. Global Ulcerative Colitis Market Competitive Dashboard
33. Key Mergers And Acquisitions In The Ulcerative Colitis Market
34. Ulcerative Colitis Market Future Outlook and Potential Analysis
35. Appendix

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model